# US 2014/0194419 A1 · Chromenone derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194419 A1
- Document ID: US20140194419A1
- Status: Published application
- Kind: A1
- Application number: 14/163,105
- Filed: 2014-01-24
- Published: 2014-07-10
- Earliest claimed: 2009-10-27
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: Bernard Christophe BARLAAM; Sebastien Louis DEGORCE; Christine Marie, Paul LAMBERT-VAN DER BREMPT; Remy Robert MORGENTIN; Patrick PLE
- Web page: https://patentgrep.com/patent/US20140194419A1

## CPC

- C07D 311/74: Benzo[b]pyrans, hydrogenated in the carbocyclic ring
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 311/22: with oxygen or sulfur atoms directly attached in position 4
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

## Claims

### Claim at position 1

-8. (canceled)

### Claim 9

A method for treating cancer in a warm blooded animal in need thereof comprising administering to the animal an effective amount of 8-((1R)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-5 carboxamide, or a pharmaceutically acceptable salt thereof in combination with an antiandrogen.

### Claim 10 (depends on 9)

A method according to claim 9, where the antiandrogen is bicalutamide.

### Claim 11 (depends on 9)

A method according to claim 9, where the cancer is prostate cancer.

### Claim 12

A method for treating cancer in a warm blooded animal in need thereof comprising administering to the animal an effective amount of 8-((1R)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-5 carboxamide, or a pharmaceutically acceptable salt thereof in combination with a taxoid.

### Claim 13 (depends on 12)

A method according to claim 12, where the taxoid is taxotere.

### Claim 14 (depends on 12)

A method according to claim 12, where the cancer is prostate cancer, breast cancer or lung cancer.

### Claim 15

A method for treating cancer in a warm blooded animal in need thereof comprising administering to the animal an effective amount of 8-((1R)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-5 carboxamide, or a pharmaceutically acceptable salt thereof in combination with a MEK kinase inhibitor.

### Claim 16 (depends on 15)

A method according to claim 15, where the cancer is lung cancer.